Genomics in Drug Discovery Webinar 1: Revolutionising Genomics through AI in Drug Discovery

On average, it takes 10.5 years for a Phase I drug to progress to regulatory approval and only ~8% of drugs get approved. The top contributing factors that spearhead drug candidate success are target identification and validation. Hence, the role of genomics in revolutionizing the way we discover, develop, and personalize drugs is becoming increasingly central.

Join us for our latest webinar series: Genomics in Drug Discovery ONLINE as we unveil the latest genomics-driven advances that are broadening the drug discovery toolkit. This series will showcase how an enhanced accuracy in identifying and validating targets increases the success rate of drugs progressing to clinical development, leading to accelerated approvals.

Register now to join the virtual series live, with 8 expert talks and live Q&As with the speakers.

By registering to this series, you will:

• Explore the role of AI/ML in data management and integration to identify mechanisms of action and facilitate drug discovery
• Discover the importance of diverse genomic datasets in developing translatable in-vitro models and in stratifying patients
• Further your understanding of the different ways that functional genomics can be applied to transform drug discovery, target validation and optimisation

**Please note that by registering for one webinar in the series, you will automatically be registered to all subsequent webinars**

Webinar 1: Revolutionizing Genomics through AI in Drug Discovery

Thursday 7th of March 2024 at 3pm BST / 4pm CET/ 10am EST

Is AI the pioneering force set to revolutionize drug discovery?

Introducing the power of AI algorithms, this webinar will delve into how AI/ML is reshaping the landscape of drug discovery. The webinar will tackle the management and integration of big data to rapidly and accurately identify potential drug targets, intricate biological networks, and ultimately provide a holistic understanding of target interactions.

Talk 1: Integrated Genomics and Transcriptomics Based Approaches for Predicting Drug Response Biomarkers - Harpreet Saini, Senior Director, Bioinformatics, Astex Pharmaceuticals

Talk 2: Omics Data Management and Analytics - Felix Francis, Senior Manager, Data Management and Analytics, Takeda

Webinar 2: Tackling Genetic Diversity through Translational Models & Patient Stratification for Effective Target Discovery

Thursday 14th of March 2024 at 3pm BST / 4pm CET/ 10am EST

90% of drugs that enter clinical development fail because they are ineffective.

This webinar will uncover how incorporating diverse genetic backgrounds contributes to the development of targeted therapeutics. The webinar will shed light on amplifying genetic diversity in preclinical and translational studies through exploring in-vitro models for indication-relevant assays and patient stratification.

Talk 1: Developing & Defining Translatable in-vitro Models & Indication Relevant Assays - Emma Laing, Director, Computational Biology, GSK

Talk 2: Biomarker-Selected Patient Stratification Driving Precision Oncology - Dipti Thakkar, Vice President, Target Biology & Pharmacology, Hummingbird Bio

Talk 3: Pulse RNA Library Screens as a Method of Target Discovery in Myeloid Malignancies - Jamshid Khorashad, Honorary Senior Lecturer & Scientific Consultant, Imperial College London

Webinar 3: Decoding Success using Functional Genomics in Drug Discovery

Thursday 21st of March 2024 at 3pm BST / 4pm CET/ 10am EST

Unravelling pathways with functional genomic tools drastically reduces drug development failures

This webinar will review how functional genomic tools can enable the systematic exploration of genetic elements for, and the rigorous validation of, novel and promising drug targets. It will demonstrate how the incorporation of functional genomic capabilities into conventional drug development pipelines is predicted to expedite the development of first-in-class therapeutics.

Talk 1: Application of CRISPR-cas9 for iPSC-Models in Drug Discovery - Matteo Martufi, Associate Director, GSK

Talk 2: Using Pooled CRISPR Screening to Drive Oncology Drug Discovery - David Walker, Group Leader Functional Genomics, Cancer Research Horizons

Talk 3: Population Level Omics for Precision Medicine - Ryan Dhindsa, Assistant Professor, PI, Baylor College of Medicine